

Discrepancies between histology and serology for the diagnosis of coeliac disease in a district general hospital: is this an unrecognised problem in other hospitals?

Rami Sweis, Leon Pee, Gray Smith-Laing

ABSTRACT – The objective of this study was to assess the increasing number of patients with positive biopsies yet negative serology at Medway Hospital, Kent, through a retrospective data collection. All coeliac serology undertaken between 2003–5 ($n=3,056$) with coeliac positive duodenal biopsy results ($n=26$) were compared. From the total number of patients with positive duodenal biopsies 10 (38.5%), 13 (50%) and 12 (46.2%) had negative anti-tTG, IgA anti-gliadin and IgG anti-gliadin serology respectively. When combining anti-tTG, IgG and IgA anti-gliadin to improve sensitivity, five patients (19.2%) had completely negative and six (23%) had equivocal serology results. This study shows that a small but significant number of cases of coeliac disease will be missed by relying on serology alone. As the diagnosis and management of disease shifts further towards general physicians and primary care, it is important that the limitations of serological testing are recognised.

KEY WORDS: coeliac disease, coeliac serology, gluten, IgA anti-endomysial antibodies, IgA anti-gliadin antibodies, IgA anti-tissue transglutaminase antibodies

Background

Coeliac disease is an inflammatory disorder of the small bowel which is a result of protein-rich amines (prolamines) that are found in wheat, barley and rye interacting with the bowel mucosa. This ‘gluten-sensitive enteropathy’ results in atrophy of the villi causing malabsorption with symptoms of diarrhoea, steatorrhoea, weight loss and anaemia. Abdominal pain, distension and other vague, non-specific symptoms such as fatigue are also common. Long-term health consequences associated with untreated coeliac disease include osteoporosis and an increased incidence of malignancy. Associated conditions include autoimmune thyroid disease, diabetes and dermatitis herpetiformis.¹ The prevalence of coeliac disease has been estimated to be as high as 1:100 in the UK and Ireland.¹

Patients can present at any age. ‘Adult’ coeliac disease often presents with iron deficiency anaemia and non-specific symptoms mimicking irritable bowel syndrome (IBS). The gold standard

method for diagnosing coeliac disease is by identifying characteristic histopathological changes from an adequate small bowel biopsy based on the modified Marsh criteria.² In 1989, serological testing was included in the criteria for the diagnosis of coeliac disease.³ Serology has progressed from the use of anti-reticulin antibodies to testing for IgA anti-gliadin antibodies, IgA anti-endomysial antibodies and more recently to ELISA for IgA anti-tissue transglutaminase antibodies.⁴ Published data on the serological testing of coeliac disease indicate both high sensitivity and specificity of these antibodies with the sensitivity and specificity of IgA anti-tissue transglutaminase antibodies being much higher (99% and >90%) than IgA anti-gliadin (46–100% and 86–100%) and IgA anti-endomysium (74–100% and 91–100%).⁵ Duodenal biopsy is still recommended as it helps stage the severity of the disease and differentiates latent disease, but there is now increasing reliance on non-invasive testing.

Pitfalls in serological testing include false negative results in the 3% of coeliac patients who are IgA deficient. In such cases, those with negative serology yet strong clinical suspicion should have their IgA status assessed and undergo IgG-based serological testing.^{6,7}

Most hospitals around the UK rely on serology and often combine tests to improve the sensitivity and specificity to near 100%. At the Medway Hospital, Kent, however, a number of patients with positive biopsies but negative serology were recorded and so a retrospective analysis of serological and histological testing for this condition was performed.

Methods and aims

The results of all coeliac serology performed between 2003 and 2005 (3,056 patients) were collected and correlated with the results of duodenal biopsies (42 patients) which fulfilled the histological criteria for coeliac disease.

At Medway Hospital three ELISA tests were performed as standard during the three years studied:

- IgA anti-gliadin antibodies
- IgG anti-gliadin antibodies
- IgA anti-tissue transglutaminase (tTG) antibodies.

Any positive anti-tTG antibodies were confirmed with immunofluorescent staining of monkey oesophagus for IgA anti-endomysial antibody. The ELISA tests were recorded in U/ml and the anti-endomysial tests recorded as an end-point titre. The reference ranges for results were <10 U negative, 10–15 U equivocal and >15 U positive.

Rami Sweis, Specialist Registrar, St Thomas’ Hospital, London;
Leon Pee, Registrar, Queen Elizabeth the Queen Mother Hospital,
Margate; Gray Smith-Laing, Consultant in Gastroenterology, Medway
Maritime Hospital, Medway

Results

Of the 3,056 patients, 42 had positive biopsies and 16 of these were diagnosed on biopsy without serology. Of the 26 remaining patients, 10 (38.5%, 95% confidence interval (CI) 20.3 to 57.8%) had negative tissue transglutaminase (anti-tTG), 13 (50%, 95% CI 30.8 to 69.2%) had negative IgA anti-gliadin and 12 (46.2%, 95% CI 26.8 to 65.2%) had negative IgG anti-gliadin. Even when combining anti-tTG with IgG and IgA anti-gliadin antibodies to improve sensitivity, five patients (19.2%, 95% CI 3.9 to 34.1%) had completely negative serology and six (23.1%, 95% CI 6.8 to 39.2%) had equivocal serology results (Table 1). None of the patients had been placed on a gluten-free diet prior to serology testing.

Discussion

A recent prospective study showed that of 2,000 patients with suspected coeliac disease, 0.4% (7/2,000) had anti-tTG negative coeliac disease, and of those diagnosed with coeliac disease on histological criteria, 9.1% (7/77) had negative anti-tTG serology.⁸ The laboratory techniques used at this hospital are standardised and similar to those used in most hospitals in the country. The retrospective study demonstrates that some cases of coeliac disease will be missed by relying on serological tests alone (see case history), and suggests that there may be an even more significant discrepancy between serology and histology, even when serological test are combined.

Some explanations for the discrepancies seen between the serological and histological results in this study might be:

- the results are based on only a small number of positive biopsies
- anti-gliadin antibody is a better marker of adherence to a gluten free diet than for the diagnosis of coeliac disease
- there may have been laboratory errors
- the published predictive values of the antibody tests quoted above may be those of tertiary centres that specialise in coeliac disease and are not representative of results produced by laboratories in district general hospitals.

However, we think it is unlikely that these factors would account for more than a small portion of the discrepancy seen.

Clinicians have grown increasingly to rely on serology for the diagnosis, and more importantly for the exclusion of

coeliac disease. This study shows that a small but significant number of cases will be missed by relying on serology alone. If these findings are replicated across the UK a sizeable number of patients will continue to suffer the consequences of untreated coeliac disease (as demonstrated by the case history). Gastroenterologists are familiar with the more protean symptoms of coeliac disease but general physicians and primary care doctors may be less familiar with the varied presentations of the condition or the pitfalls in diagnosis. As the diagnosis and management of disease shifts ever further towards general medicine and primary care, it is important that the limitations of serological testing are recognised by all physicians. Where there is doubt about the diagnosis it is recommended that the opinion of a gastroenterologist be sought and duodenal biopsies be performed.

Case history

A 51-year-old taxi driver had attended outpatient clinics for many years with symptoms interpreted as IBS characterised by intermittent bouts of abdominal pain and diarrhoea. He had had these symptoms for over 25 years. He had previously been referred to the surgical outpatients in 1999 and a




Fig 1. Haematoxylin-eosin stained celiac epithelium showing the characteristic infiltration of intraepithelial lymphocytes and flattened villi.

Table 1. Serology results in patients with positive biopsies (n=26).

IgA anti-gliadin Ab		IgG anti-gliadin Ab		IgA anti-tissue transglutaminase antibodies		IgA/IgG anti-gliadin+anti-tissue transglutaminase antibodies	
Neg	Equiv	Neg	Equiv	Neg	Equiv	Neg	Equiv
13	4	12	3	10	2	5	6
50%	15.4%	46.2%	11.5%	38.5%	7.7%	19.2%	23.1%
(30.8–69.2%)	(1.3–28.7%)	(26.8–65.2%)	(1–23%)	(20.3–57.8%)	(2.6–17.8%)	(3.9–34.1%)	(6.8–39.2%)

gastroscopy, flexible sigmoidoscopy, barium enema and abdominal ultrasound scan were unremarkable. More recently he had lost a stone in weight and developed iron deficiency anaemia and was referred to the gastroenterology clinic. His coeliac antibodies (anti-gliadin IgA/IgG and anti-tTG IgA) performed on 17 May 2005 were negative. A repeat endoscopy on 3 June 2005 showed grossly abnormal duodenal mucosa with a mosaic pattern and duodenal biopsies confirmed the presence of coeliac disease (Fig 1). A gluten free diet resulted in the resolution of his anaemia and symptoms and a weight gain of 15 kg.

Acknowledgement

We would like to thank Dr Matthew Johnson, Consultant in Gastroenterology, Luton and Dunstable Hospital and George Taylor, Lead Lab Manager in Immunology and Histology, Medway Hospital, for their help and advice.

References

- 1 Maki M, Collin P. Coeliac disease. *Lancet* 1997;349:1755–9.
- 2 Oberhuber G, Granditsch G, Vogelsang H. The histopathology of

- coeliac disease: time for a standardized report scheme for pathologists. *Eur J Gastroenterol Hepatol* 1999;11:1185–94.
- 3 Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. *Arch Dis Child* 1990;65:909–10.
- 4 Salaken S, Halttunen T, Laurila K *et al*. Tissue transglutaminase enzyme-linked immunosorbent assay in detecting celiac disease. *Gastroenterology* 1998;115:1322–8.
- 5 Dahele AV, Aldhous MC, Humphreys K, Ghosh S. Serum IgA tissue transglutaminase antibodies in coeliac disease and other gastrointestinal diseases. *QJM* 2001;94:195–5.
- 6 Cataldo F, Marino V, Ventura A, Bottaro G, Corazza GR. Prevalence and clinical features of selective immunoglobulin A deficiency in coeliac disease: an Italian multicentre study. Italian Society of Paediatric Gastroenterology and Hepatology (SIGEP) and 'Club del Tenue' Working Groups on Coeliac Disease. *Gut* 1998;42:362–5.
- 7 Chorzelski TP, Beutner EH, Zalewski T. *Serologic diagnosis of celiac disease*. Boston, MA: CRC Press, 1990.
- 8 Hopper AD, Cross SS, Hurlstone DP *et al*. Pre-endoscopy serological testing for coeliac disease: evaluation of a clinical decision tool. *BMJ* 2007;334:729.

Address for correspondence: Dr G Smith-Laing, Medway Maritime Hospital, Windmill Road, Gillingham, Kent ME7 5NY. Email: gray.smith-laing@medway.nhs.uk

The prevention, diagnosis, referral and management of melanoma of the skin Concise guidelines

Melanoma of the skin is an increasingly common tumour which usually occurs in white-skinned people, particularly those with pale skin and many moles. A fifth of cases occur in young adults, so the cancer has a large impact in terms of years of life lost. Melanoma often grows slowly at first, and therefore offers the opportunity for health professionals to detect and remove lesions at a curable stage.

These guidelines have been developed to provide clinicians with a practical, visual guide to recognising melanoma of the skin, and include an extensive series of photographs of moles, melanomas and other skin lesions. They are an essential guide for physicians, general practitioners and other healthcare professionals who may be able to recognise melanoma and reduce mortality.

This guideline is number 7 in the Concise Guidance to Good Practice series – a series of evidence-based guidelines for clinical management.

Contents

- Summary of the guidelines
- What is melanoma and what is its epidemiology?
- Types of melanoma
- Who is at risk of melanoma?
- Where do they occur on the body?
- What is the relationship between moles and melanoma?
- What are the symptoms and signs of a melanoma?
- What are the diagnostic signs of a melanoma?
- Management



**Royal College
of Physicians**
Setting higher medical standards



Published September 2007
ISBN 978-1-86016-301-2
Price: £10.00 UK, £12.00 overseas
(prices include postage and packing)